Synthesis and anti-tubercular activity of novel alkyl substituted riminophenazine derivatives

Yaoxue Xuebao

Volumn 47, Issue 6, 2012, Pages 745-754

  Li, Yu Li ^a   Zhang, Chun Lin ^a   Zhang, Dong Feng ^a   Lu, Yu ^b   Wang, Bin ^b   Zheng, Mei Qin ^b   Li, Chun ^a   Yin, Da Li ^a   Huang, Hai Hong ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Alkyl substituent; Anti tubercular activity; Clofazimine; Lipophilicity; Riminophenazine

Indexed keywords

2 (4 CHLOROANILINO) 5 CYCLOPROPYL 3 (4 METHOXYCYCLOHEXYL)IMINO 3,5 DIHYDROPHENAZINE; ALKYL GROUP; CLOFAZIMINE; CLOFAZIMINE DERIVATIVE; CYCLOPROPANE DERIVATIVE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; LIPOPHILICITY; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN;

ANIMALS; ANTITUBERCULAR AGENTS; CERCOPITHECUS AETHIOPS; DRUG DESIGN; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; PHENAZINES; VERO CELLS;

EID: 84865317399     PISSN: 05134870     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ma Z, Lienhardt C, McIlleron H, et al. Global tuberculosis drug development pipeline: the need and the reality [J]. Lancet, 2010, 375: 2100-2109.
2. China Tuberculosis Control Collaboration. The effect of tuberculosis control in China [J]. Lancet, 2004, 364: 417-422.
3. Koul A, Arnoult E, Lounis N, et al. The challenge of new drug discovery for tuberculosis [J]. Nature, 2011, 469: 483-490.
4. Barry VC, Belton JG, Conalty ML, et al. A new series of phenazines (rimino-compounds) with high antituberculosis activity [J]. Nature, 1957, 179: 1013-1015.
5. Cholo MC, Steel HC, Fourie PB, et al. Clofazimine: current status and future prospects [J]. J Antimicrob Chemother, 2012, 67: 290-298.
6. O'Connor R, O'Sullivan JF, O'Kennedy R. The pharmacology, metabolism, and chemistry of clofazimine [J]. Drug Metab Rev, 1995, 27: 591-614.
7. Kikuchi M, Miyamoto H, Itotani M, et al. Dihydrophenazine derivative: JP, 11060563 [P]. 1999-03-02
8. Kamal A, Hari Babu A, Venkata Ramana A, et al. Antitubercular agents. Part 1: synthesis of phthalimido- and naphthalimido-linked phenazines as new prototype antitubercular agents [J]. Bioorg Med Chem Lett, 2005, 15: 1923-1926.
9. O'Connor R, O'Sullivan JF, O'Kennedy R. Determination of serum and tissue levels of phenazines including clofazimine [J]. J Chromatogr B, 1996, 681: 307-315.
10. Reddy VM, O'Sullivan JF, Gangadharam PRJ. Antimycobacterial activities of riminophenazines [J]. J Antimicrob Chemother, 1999, 43: 615-623.
11. Zhu YF, Lin GQ, Chen YQ. New modified preparation of 2-nitrodiarylamines [J]. Synthesis, 1990, 5: 430.
12. O'Sullivan JF, Conalty ML, Morrison NE. Clofazimine analogues active against a clofazimine-resistant organism [J]. J Med Chem, 1988, 31: 567-572.
13. Collins LA, Franzblau SG. Microplate alamar blue assay versus BACTEC 460 system for high-throughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium [J]. Antimicrob Agents Chemother, 1997, 41: 1004-1009.
14. Lu Y, Zheng M, Wang B, et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation [J]. Antimicrob Agents Chemother, 2011, 55: 5185-5193.
15. Falzari K, Zhu ZH, Pan DH, et al. In vitro and in vivo activities of macrolide derivatives against Mycobacterium tuberculosis [J]. Antimicrob Agents Chemother, 2005, 49: 1447-1454.